{"disease":{"id":"chronic-idiopathic-urticaria","name":"Chronic idiopathic urticaria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":11,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"omalizumab","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolair","generic_name":"omalizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"Anti-IgE [EPC]","quality_score":52,"revenue":"3200","mechanism":null},{"drug_id":"fexofenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allegra","generic_name":"fexofenadine","company_name":"Generic (originally Hoechst Marion Roussel/Sanofi)","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"terfenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seldane","generic_name":"TERFENADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"High Risk QT Prolonging Agents","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"astemizole","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hismanal","generic_name":"ASTEMIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"cetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyrtec","generic_name":"cetirizine","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"xolair","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xolair","company_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"desloratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clarinex","generic_name":"desloratadine","company_name":"Generic (originally Schering-Plough/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties."},{"drug_id":"loratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claritin","generic_name":"loratadine","company_name":"Generic (originally Schering-Plough)","drug_phase":"marketed","molecular_target":"Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ebastine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bastel","generic_name":"EBASTINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"ebastine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"levocetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyzal","generic_name":"LEVOCETIRIZINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"desloratadin","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Desloratadin","company_name":"Max Zeller Soehne AG","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05774639","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Kashiv BioSciences, LLC","has_results":false},{"nct_id":"NCT05936567","title":"Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT00783354","title":"A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT00757562","title":"Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT03858634","title":"A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT07486583","title":"Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04175704","title":"Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"United BioPharma","has_results":false},{"nct_id":"NCT03406325","title":"Mast Cell Activation Test in Allergic Disease","phase":"","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Hong Kong Sanatorium & Hospital","has_results":true},{"nct_id":"NCT03183024","title":"Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Jonathan A. Bernstein, MD","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}